Compare Invesco WilderHill Clean Energy ETF (PBW) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco WilderHill Clean Energy ETF vs Sanofi SA — how do they compare? Invesco WilderHill Clean Energy ETF trades at $33.85, while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA pays a 5.53% dividend while Invesco WilderHill Clean Energy ETF pays none, and Invesco WilderHill Clean Energy ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| PBW | SNY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $52.34 |
52-Week Low | $22.23 | $41.33 |
Market Cap | — | $104.85B |
Enterprise Value | — | $121.38B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBW trades at $33.21, down 0.54% today, amid a bearish technical signal with moving averages indicating strong selling pressure. The ETF shows oversold conditions on short-term RSI readings but faces headwinds from sector volatility. Recent news highlights clean energy's potential tailwinds from energy security concerns and data center demand, though the fund remains sensitive to interest rate movements and semiconductor market swings.
The outlook for PBW is cautious; while clean energy thematic demand provides long-term opportunity, near-term risks include interest rate sensitivity and tech sector correlation. Investors face volatility from macroeconomic factors and sector-specific pressures, requiring careful risk assessment amid mixed technical and fundamental signals.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
